Drugs / VENBETA6890
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06896136 | Feb → May 2025 | intestinal infectious disease | Mark Klempner | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VENBETA6890 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06896136 ↗ |
| Modality | Monoclonal antibody | “human monoclonal IgA” NCT06896136 ↗ |
| Route | Oral | “orally administered” NCT06896136 ↗ |